🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

518 results for “Cho” Clear

  1. -, DOCETAXEL , DEXAMETHASONE , -, -, MK-2870, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, PEMETREXED

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  2. 1.0mg/kg/day PRAX-562

    Chongqing Precision Biotech Co., Ltd

    Developmental and Epileptic Encephalopathy 1

    phase 3 small molecule active

    1 trial

  3. 18F fluciclovine

    Chongqing Precision Biotech Co., Ltd

    Brain Metastases

    phase 3 small molecule completed

    2 trials

  4. 1mg elsunersen

    Chongqing Precision Biotech Co., Ltd

    Epileptic Encephalopathy

    phase 3 small molecule active

    1 trial

  5. 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks

    Chongqing Precision Biotech Co., Ltd

    Focal Seizure

    phase 3 small molecule active

    1 trial

  6. 3-N-butylphthalide

    Second Affiliated Hospital, School of Medicine, Zhejiang University

    Multiple System Atrophy

    phase 3 small molecule active

    1 trial

  7. 40 mg/day vormatrogine for 12 weeks

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  8. 60 mg ulixacaltamide

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 3 small molecule active

    1 trial

  9. A 52-Week, Open-Label Extension Study of ACP-204 in Adults with Alzheimer's Disease Psychosis

    Lacuna Pharma Pty Ltd

    Alzheimer's Disease Psychosis

    phase 3 other active

    1 trial

  10. A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

    Lacuna Pharma Pty Ltd

    Lewy body Dementia psychosis (LBDP)

    phase 3 other active

    1 trial

  11. ACP-204

    Acadia Pharmaceuticals B.V.

    Alzheimer's Disease Psychosis

    phase 3 small molecule active

    2 trials

  12. ACP-204

    Acadia Pharmaceuticals B.V.

    Lewy Body Dementia Psychosis

    phase 3 small molecule active

    2 trials

  13. AG-120/S95031 250mg film-coated tablet, Ivosidenib-matched Placebo Tablets

    The George Institute

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  14. ALXN1720 Placebo Product, Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  15. ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

    Gilead Sciences Pty Limited

    Primary Biliary Cholangitis

    phase 3 other active

    1 trial

  16. AZD0780

    AstraZeneca

    Heterozygous Familial Hypercholesterolaemia

    phase 3 small molecule active

    1 trial

  17. AZD0780 Placebo, AZD0780

    AstraZeneca AB

    Heterozygous familial hypercholesterolaemia

    phase 3 small molecule active

    1 trial

  18. Albuterol Spiromax

    Teva Pharma GmbH

    Exercise-Induced Bronchoconstriction (EIB)

    phase 3 small molecule completed

    1 trial

  19. Alirocumab

    Sanofi Pasteur

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  20. Alirocumab

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    2 trials

  21. Alirocumab

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  22. Alirocumab

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule active

    18 trials

  23. Alirocumab SAR236553

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    1 trial

  24. Apremilast, Apremilast, Apremilast

    Amgen

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources